In a subgroup analysis, patients who were admitted to the ICU before their first dose of ceftriaxone and PPI were excluded. This was based on the rationale that ICU admission at baseline could be a confounder, because patients in ICUs were more likely to receive PPI therapy for prophylaxis postintubation or treatment of gastrointestinal bleed.